Blockchain Registration Transaction Record

Oncotelic Doses First Patient in Phase 1b Trial of Sapu003 for Solid Tumors

Oncotelic Therapeutics (OTLC) and Sapu Nano dose first patient in Phase 1b trial of Sapu003, a IV everolimus formulation for advanced mTOR-sensitive solid tumors, including HR+/HER2- breast cancer.

This news matters because Sapu003's novel IV formulation of everolimus could overcome the limitations of oral delivery, such as variable absorption and toxicity, potentially offering a more effective and tolerable treatment for patients with advanced mTOR-sensitive solid tumors, including breast cancer. If successful, it may set a new standard for everolimus administration and improve outcomes for cancer patients.